Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents
摘要:
The first direct activator of BAX, a pro-apoptotic member of the BCL-2 family, has been recently identified. Herein, a structure-based lead optimization turned out into a small series of analogues, where 8 is the most potent compound published so far. 8 was used as pharmacological tool to ascertain, for the first time, the anticancer potential of BAX direct activators and the obtained results would suggest that BAX direct activators are potential future anticancer drugs rather than venoms.
[EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
申请人:ALMIRALL SA
公开号:WO2014060432A1
公开(公告)日:2014-04-24
New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)
[EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
申请人:GLAXOSMITHKLINE LLC
公开号:WO2011119704A1
公开(公告)日:2011-09-29
The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
本发明涉及喹啉类似物、含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。
Discovery of <i>meta</i>-Amido Bromophenols as New Antitubercular Agents
作者:Jie Liang、Yun-xiang Tang、Xiang-zheng Tang、Hua-ju Liang、Yamin Gao、Cuiting Fang、Tian-yu Zhang、Ming Yan
DOI:10.1248/cpb.c18-00917
日期:2019.4.1
Gram-positive and Gram-negative bacteria. Moderate cytotoxicities and good metabolic stability were observed for the selected compounds. The results demonstrated meta-amido bromophenols as a new class of antitubercularagents with good potentials.
NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
申请人:EIS Knut
公开号:US20090226377A1
公开(公告)日:2009-09-10
The present invention relates to a quinoline or quinazoline derivative having the general formula (A):
in which R
3
, R
4
, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I,
wherein the variables Q1, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.